Pacific Biosciences
PACB
208 hedge funds and large institutions have $238M invested in Pacific Biosciences in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 61 reducing their positions, and 25 closing their positions.
181% more call options, than puts
Call options by funds: $2.87M | Put options by funds: $1.02M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
0% more funds holding
Funds holding: 207 → 208 (+1)
3% less capital invested
Capital invested by funds: $246M → $238M (-$8M)
8% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 61
4.14% less ownership
Funds ownership: 66.14% → 62% (-4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.48M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.38M |
| 3 |
PD
Point72 (DIFC)
Dubai,
United Arab Emirates
|
+$2.45M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.04M |
| 5 |
Squarepoint
New York
|
+$863K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
Madrone Advisors
Menlo Park,
California
|
-$16M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$7.28M |
| 3 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$3.64M |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.34M |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$1.28M |
PACB Hedge Fund Activity: Q3 2025 in Review
208 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2025, worth a combined $238M — down 3.3% from $246M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PACB positions and 25 closed out — a net gain of 3 holders — while 56 added to existing stakes and 61 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.48M. The largest seller was Madrone Advisors, cutting an estimated $16M.
- 208 institutional investors held Pacific Biosciences (PACB) as of Q3 2025, up from 207 in Q2 2025.
- Funds reported $238M of Pacific Biosciences stock for Q3 2025, down 3.3% quarter-over-quarter.
- 28 funds opened new Pacific Biosciences positions in Q3 2025 and 25 closed out, a net change of +3 holders.
- The largest Pacific Biosciences buyer in Q3 2025 was Millennium Management, an estimated $5.48M added.
- The largest Pacific Biosciences seller in Q3 2025 was Madrone Advisors, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2025.